Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2016-10-12 Capital/Financing Update
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the execution of a demand promissory note, which is a financing activity involving a loan agreement. There are no financial statements or comprehensive financial data presented, only disclosure of a material definitive agreement related to financing. This fits the category of Capital/Financing Update (CAP). The document length is short (2966 characters), and it is not an announcement of a report but a standalone filing about a financing event.
2016-10-12 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes termination of material agreements, amendments to articles of incorporation, shareholder meeting voting results, and other corporate governance matters. It is not a full annual or quarterly report, nor is it a transcript or earnings release. The detailed voting results and corporate actions indicate it is primarily reporting on shareholder meeting outcomes and corporate governance changes. Therefore, the most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length and detail support this classification with high confidence.
2016-09-21 English
FORM 10-Q
Interim / Quarterly Report 9M 2016
2016-08-15 English
DEF 14A
Proxy Solicitation & Information Statement
2016-08-11 English
Regulatory Filings 2016
Regulatory Filings
2016-08-11 English
PRER 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and the title 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934'. It is related to the solicitation of proxies for the Annual Meeting of Stockholders of Citius Pharmaceuticals, Inc. The content includes detailed information about the meeting agenda, voting procedures, and proxy solicitation, which are typical features of a Proxy Solicitation & Information Statement. It is not an Annual Report, Earnings Release, or any other financial report, but rather a document designed to inform shareholders and solicit their votes. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content support this classification with high confidence.
2016-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.